Affymax Inc. and Takeda Pharmaceutical Company Ltd. said Thursday they agreed to suspend co-development of Hematide for treatment of chemotherapy-induced anemia and instead focus all development efforts for the drug on the treatment of chronic kidney disease related anemia. (AFFY)

Lees meer..